Companies · Pharmaceuticals
Chesterfield · Pharmaceuticals
Diligence memoA one-page analyst read on Kv Pharmaceutical Co /De/ — recommendation, valuation, rhythm, risks.→Kv Pharmaceutical Co /De/ looks over-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Kv Pharmaceutical Co /De/ is one of 1613 Pharmaceuticals companies tracked from Chesterfield. By capital raised it ranks among the largest (ahead of 99% of sector peers), and among the largest by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series C — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.
Round size and date are reported; the stage label is inferred from round size (latest is Series D+ — a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.
Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 99% of sector peers (real $). Modeled value above 99% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #1 of 6.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Kv Pharmaceutical Co /De/ this company | Series D+ | $526.0M | $9.2B | 1.61× |
| Clovis Oncology, Inc. | Series D+ | $358.3M | $6.8B | 1.18× |
| Opko Health, Inc. | Series D+ | $206.0M | $6.2B | 1.08× |
| Horizon Pharma, Inc. | Series D+ | $308.4M | $5.3B | 0.92× |
| HLS Therapeutics Inc. | Series D+ | $142.8M | $1.1B | 0.18× |
| Biotie Therapies Corp. | Series D+ | $149.8M | $214.0M | 0.04× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series A | $7.6M | 2010-11-17 | $34.3M | $233.9M | 90% |
| Series B | $32.3M | 2011-02-17 | $179.7M | $1.1B | 90% |
| Series D+ | $225.0M | 2011-03-17 | $1.9B | $7.9B | 90% |
| Series D+ | $210K | 2012-06-05 | $1.8M | $7.4M | 90% |
| Series D+ | $260.9M | 2013-06-06 | $2.2B | $9.2B | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Ana I. Stancic | — | 1 other | 2010-11 |
| Robert E. Baldini | — | 1 other | 2010-11 |
| David D. Sidransky | — | — | 2010-11 |
| David S. Hermelin | — | — | 2010-11 |
| Eric J Haron | — | — | 2013-06 |
| Gregory J Divis | — | — | 2013-06 |
| Gregory J. Divis, Jr. | — | — | 2010-11 |
| Gregory S. Bentley | — | — | 2010-11 |
| Joe J McGinnis | — | — | 2013-06 |
| Jonathan J Siegel | — | — | 2013-06 |
| Joseph D. Lehrer | — | — | 2010-11 |
| Mark A. Dow | — | — | 2010-11 |
| Patrick J Christmas | — | — | 2013-06 |
| Steve J Nielson | — | — | 2013-06 |
| Thomas S. McHugh | — | — | 2010-11 |
Kv Pharmaceutical Co /De/ is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. | Pharmaceuticals | Series D+ | $527.4M | $2.4B | same sector · same stage |
| Recursion Pharmaceuticals, Inc. | Pharmaceuticals | Series D+ | $478.3M | $8.3B | same sector · same stage |
| Lexicon Pharmaceuticals, Inc. | Pharmaceuticals | Series D+ | $446.0M | $374.2M | same sector · same stage |
| Precigen, Inc. | Pharmaceuticals | Series D+ | $624.0M | $405.3M | same sector · same stage |
| Galecto, Inc. | Pharmaceuticals | Series D+ | $428.3M | $2.0B | same sector · same stage |
| Paragon Biosciences Emalex Capital, Inc. | Pharmaceuticals | Series D+ | $376.8M | $5.5B | same sector · same stage |
| TrialSpark, Inc. | Pharmaceuticals | Series D+ | $372.2M | $4.1B | same sector · same stage |
| Clovis Oncology, Inc. | Pharmaceuticals | Series D+ | $358.3M | $6.8B | same sector · same stage |
See where Kv Pharmaceutical Co /De/ sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Kv Pharmaceutical Co /De/, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.